- Home
- BCG vs KTTA Comparison
BCG vs KTTA Comparison
Compare BCG & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCG | KTTA |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.6M | 26.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BCG | KTTA |
|---|---|---|
| Price | $2.69 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 44.3K | ★ 578.4K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $178,203,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $73.62 | ★ N/A |
| Revenue Growth | ★ 10.19 | N/A |
| 52 Week Low | $1.36 | $0.28 |
| 52 Week High | $5.81 | $3.85 |
Technical Indicators
Market Signals| Indicator | BCG | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 61.35 | 51.66 |
| Support Level | $2.17 | $1.09 |
| Resistance Level | $3.25 | $1.30 |
| Average True Range (ATR) | 0.29 | 0.09 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 68.46 | 30.34 |
Price Performance
Historical ComparisonAbout BCG Binah Capital Group Inc.
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).